Neuroendocrine Carcinomas
10 clinical trials · Condition
◉ Watch Neuroendocrine Carcinomas
| Record | Firm | Date |
|---|---|---|
| Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer (NCT02820857) | Hospices Civils de Lyon | 2017-09-04 |
| Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas (NCT04122911) | National Cancer Institute, Naples | 2017-01-29 |
| Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin (NCT02695459) | The Netherlands Cancer Institute | 2016-03-30 |
| Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients (NCT02457273) | National Health Research Institutes, Taiwan | 2015-07-04 |
| Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors (NCT01203306) | University of Turin, Italy | 2006-01-01 |
Track Neuroendocrine Carcinomas automatically
Every clearance here is in the API, with alerts when new ones post.